NeuroInsights unveils expanded fourth edition of comprehensive market analysis and strategic investment report at Neurotech Industry Conference
SAN FRANCISCO and BOSTON, May 8 /PRNewswire/ -- NeuroInsights, the neurotech market authority, announced today the release of the organization's fourth annual comprehensive investment guide and market analysis of the global neurological disease and psychiatric illness markets. Unveiled during the annual Neurotech Industry Investing and Partnering Conference in Boston, this 400-page report enables investors, companies and governments to assess opportunities, calculate risks and understand the dynamics of this continually changing market.
The Neurotechnology Industry 2008 Report: Drugs, Devices and Diagnostics for the Brain and Nervous System tracks market movements that help guide strategic business development and investment decisions in neurotech. This year's report provides an in-depth look at more than 16 brain and nervous system disorders and treatments in development at over 500 public and private companies, including: Alzheimer's disease, addiction, ADHD, anxiety, depression, epilepsy, migraine, mild cognitive impairment, multiple sclerosis, obesity, pain, Parkinson's disease, schizophrenia, age-related macular degeneration, sensory disorders, sleep disorders, stroke and traumatic brain injury. Corporate financing, market activity, growth drivers and global industry conditions that make up the obstacles and opportunities facing the industry are fully assessed with detailed insights.
Specific findings from the Neurotechnology Industry 2008 Report show
that in 2007:
-- Brain-related illnesses represent the largest unmet medical market with
two billion people worldwide
-- Venture capital investment in neurotechnology reached an all-time high
at $1.77 billion
-- More than 250 investors participated in neurotech financings
-- Global neurotech industry revenues rose 8.3% to $130.5 billion
-- Neuropharmaceuticals recorded revenues of $109 billion and 8% annual
-- Neurodevices recorded revenues of $5.5 billion and 22% annual growth
-- Neurodiagnostics recorded revenues of $16 billion and 6% annual growth
"The neurotechnology industry made substantial gains in 2007, which has continued into 2008," said Casey Lynch, Managing Director of NeuroInsights. "Commercial neuroscience represents one of the fastest-growing and critically needed sectors of the healthcare industry. In 2007, this was underscored in the launch of several important industry initiatives, including the creation of the NASDAQ NeuroInsights Neurotech Index in September."
Specific milestones from the report were presented during NeuroInsights' annual Neurotech Industry Investing and Partnering Conference, hosted in partnership with the Neurotechnology Industry Organization. This conference, being held at the Westin Copley Place in Boston today and tomorrow, is the premier global forum where investors, executives, entrepreneurs, scientists and others involved in the development of new treatments and diagnostics for the brain and nervous system come together to shape the future of their organization and the industry.
The Neurotechnology Industry 2008 Report: Drugs, Devices and Diagnostics for the Brain and Nervous System is now available for purchase in book or digital format at http://www.neuroinsights.com/marketreports/marketreport2008.html
NeuroInsights is the world's leading neurotechnology research and
advisory firm. As the neurotechnology market authority, NeuroInsights helps
investors, industry and society understand and profit from the rapid growth
in drugs, devices and diagnostics for the brain and nervous system.
NeuroInsights provides market reports, investment information, industry
events and strategic advisory services to venture funds, startups,
corporations, governments and financial institutions. For more information,
Copyright©2008 PR Newswire.
All rights reserved